NCT02392507View on ClinicalTrials.gov

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

PHASE2CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

October 12, 2015

Primary Completion Date

January 29, 2018

Study Completion Date

November 6, 2019

Conditions

Carcinoma, Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Necitumumab

Administered IV

DRUG

Nab-Paclitaxel

Administered IV

DRUG

Carboplatin

Administered IV

Trial Locations (1)

32804

Florida Hospital Cancer Institute, Orlando

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Celgene

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY